Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) has issued an announcement.
Mayne Pharma has detailed the equity-based incentives to be granted to its new CEO, Aaron Gray, under the company’s Omnibus Equity Incentive Plan, including a US$300,000 sign-on bonus in Restricted Stock Unit Performance Rights and a pro-rated FY26 long-term incentive grant valued at US$654,781. The package, which converts grant values into equity based on the five-day volume weighted average share price and splits the LTI one-third into RSUs and two-thirds into performance rights, is designed to align Gray’s remuneration with shareholder value creation while confirming he has no role in determining his own incentives and allowing the board flexibility on settlement and dividend-equivalent treatment.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an ASX-listed specialty pharmaceutical company focused on commercialising novel medicines that are safer and more accessible for patients. The company is a market leader in dermatology and women’s health in the United States and provides contract development and manufacturing services globally, leveraging a 40-year track record in oral drug delivery innovation.
Average Trading Volume: 469,871
Technical Sentiment Signal: Sell
Current Market Cap: A$213.7M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.